A randomised study about the effect on survival of hormonal therapy versus hormonal therapy plus local external radiation therapy in patients with primary diagnosed metastasised (M+) prostate cancer
Not Applicable
Completed
- Conditions
- Malignant neoplasm of prostateCancerProstate cancer
- Registration Number
- ISRCTN06890529
- Lead Sponsor
- Onze Lieve Vrouwe Gasthuis (OLVG) (The Netherlands)
- Brief Summary
2018 survival results in https://www.ncbi.nlm.nih.gov/pubmed/30266309
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 425
Inclusion Criteria
1. Histologically proven adenocarcinoma of the prostate
2. Stage T1-4, G1-3, N0-2, M1
3. Bone metastases diagnosed with a bonescan
Exclusion Criteria
1. Start therapy more than 8 weeks after the initial diagnoses
2. Other treatment for prostate cancer before start of the study therapy
3. Other malignancies except skin carcinoma
4. Prostate specific antigen (PSA) less than 20 ng/ml
5. Aged greater than 80 years
6. Participation in another protocol
7. Not capable of filling out quality of life questionnaires
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival
- Secondary Outcome Measures
Name Time Method 1. Biochemical progression<br>2. Health-related quality of life